DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy

Sponsor
Novo Nordisk A/S
Study ID
NCT05755360
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Participants will be treated with commercially available oral semaglutide according to routine clinical practice at the discretion of the treating physician. The decision to switch from DPP4i treatment to oral semaglutide is at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.

Study Details

The purpose of the study is to look at the change in blood sugar levels in people with type 2 diabetes who change their treatment from DPP4i to oral semaglutide. Participant will get oral semaglutide as prescribed by the study doctor. The study will last for about 5-6 months. Participants will be asked to complete two questionnaires. One will be about eating behaviour and the other one will be diabetes related. Participant will complete this questionnaire during the normal scheduled visit with study doctor. Participants will be asked questions about their health and diabetes treatment and lab tests as part of their normal doctor's appointment.

Key Dates

Start date
Feb 21, 2023
Status verified
Sep 2025
Primary completion
Oct 21, 2024
Completion
Oct 21, 2024

Study Design

Enrollment
291 participants (actual)

Arms

  • Arm: Participants with T2D
    Participants will be treated with commercially available oral semaglutide according to routine clinical practice at the discretion of the treating physician.

Primary Outcome Measure

Absolute change in glycated haemoglobin (HbA1c) (percentage [%]-point) [ Time Frame: From informed consent and treatment initiation (week 0) to end of study (week 40 ± 4 weeks) ]

Related Studies